BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1116 related articles for article (PubMed ID: 16492148)

  • 1. Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds.
    Dalgarno D; Stehle T; Narula S; Schelling P; van Schravendijk MR; Adams S; Andrade L; Keats J; Ram M; Jin L; Grossman T; MacNeil I; Metcalf C; Shakespeare W; Wang Y; Keenan T; Sundaramoorthi R; Bohacek R; Weigele M; Sawyer T
    Chem Biol Drug Des; 2006 Jan; 67(1):46-57. PubMed ID: 16492148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SAR of carbon-linked, 2-substituted purines: synthesis and characterization of AP23451 as a novel bone-targeted inhibitor of Src tyrosine kinase with in vivo anti-resorptive activity.
    Shakespeare WC; Wang Y; Bohacek R; Keenan T; Sundaramoorthi R; Metcalf C; Dilauro A; Roeloffzen S; Liu S; Saltmarsh J; Paramanathan G; Dalgarno D; Narula S; Pradeepan S; van Schravendijk MR; Keats J; Ram M; Liou S; Adams S; Wardwell S; Bogus J; Iuliucci J; Weigele M; Xing L; Boyce B; Sawyer TK
    Chem Biol Drug Des; 2008 Feb; 71(2):97-105. PubMed ID: 18179464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors.
    Chang YT; Gray NS; Rosania GR; Sutherlin DP; Kwon S; Norman TC; Sarohia R; Leost M; Meijer L; Schultz PG
    Chem Biol; 1999 Jun; 6(6):361-75. PubMed ID: 10375538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel bone-targeted Src tyrosine kinase inhibitor drug discovery.
    Shakespeare WC; Metcalf CA; Wang Y; Sundaramoorthi R; Keenan T; Weigele M; Bohacek RS; Dalgarno DC; Sawyer TK
    Curr Opin Drug Discov Devel; 2003 Sep; 6(5):729-41. PubMed ID: 14579523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lck associates with and is activated by Kit in a small cell lung cancer cell line: inhibition of SCF-mediated growth by the Src family kinase inhibitor PP1.
    Krystal GW; DeBerry CS; Linnekin D; Litz J
    Cancer Res; 1998 Oct; 58(20):4660-6. PubMed ID: 9788619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R.
    Traxler P; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
    J Pharm Belg; 1997; 52(2):88-96. PubMed ID: 9193132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-activity relationships in purine-based inhibitor binding to HSP90 isoforms.
    Wright L; Barril X; Dymock B; Sheridan L; Surgenor A; Beswick M; Drysdale M; Collier A; Massey A; Davies N; Fink A; Fromont C; Aherne W; Boxall K; Sharp S; Workman P; Hubbard RE
    Chem Biol; 2004 Jun; 11(6):775-85. PubMed ID: 15217611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase.
    Traxler PM; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
    J Med Chem; 1996 Jun; 39(12):2285-92. PubMed ID: 8691423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of non-phosphate-containing small molecular weight inhibitors of the tyrosine kinase p56 Lck SH2 domain via in silico screening against the pY + 3 binding site.
    Huang N; Nagarsekar A; Xia G; Hayashi J; MacKerell AD
    J Med Chem; 2004 Jul; 47(14):3502-11. PubMed ID: 15214778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of novel purine derivatives with potent and selective inhibitory activity against c-Src tyrosine kinase.
    Huang H; Ma J; Shi J; Meng L; Jiang H; Ding J; Liu H
    Bioorg Med Chem; 2010 Jul; 18(13):4615-24. PubMed ID: 20570525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors.
    Zhu X; Kim JL; Newcomb JR; Rose PE; Stover DR; Toledo LM; Zhao H; Morgenstern KA
    Structure; 1999 Jun; 7(6):651-61. PubMed ID: 10404594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crystal structures of active SRC kinase domain complexes.
    Breitenlechner CB; Kairies NA; Honold K; Scheiblich S; Koll H; Greiter E; Koch S; Schäfer W; Huber R; Engh RA
    J Mol Biol; 2005 Oct; 353(2):222-31. PubMed ID: 16168436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of a novel series of potent and selective substrate-based inhibitors of p60c-src protein tyrosine kinase: conformational and topographical constraints in peptide design.
    Alfaro-Lopez J; Yuan W; Phan BC; Kamath J; Lou Q; Lam KS; Hruby VJ
    J Med Chem; 1998 Jun; 41(13):2252-60. PubMed ID: 9632358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural determinants of CDK4 inhibition and design of selective ATP competitive inhibitors.
    McInnes C; Wang S; Anderson S; O'Boyle J; Jackson W; Kontopidis G; Meades C; Mezna M; Thomas M; Wood G; Lane DP; Fischer PM
    Chem Biol; 2004 Apr; 11(4):525-34. PubMed ID: 15123247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular basis for regulation of Src by the docking protein p130Cas.
    Nasertorabi F; Tars K; Becherer K; Kodandapani R; Liljas L; Vuori K; Ely KR
    J Mol Recognit; 2006; 19(1):30-8. PubMed ID: 16245368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specificity of alpha-cyano-beta-hydroxy-beta-methyl-n-[4-(trifluoromethoxy)phe nyl]-propenamide as an inhibitor of the epidermal growth factor receptor tyrosine kinase.
    Ghosh S; Zheng Y; Jun X; Mahajan S; Mao C; Sudbeck EA; Uckun FM
    Clin Cancer Res; 1999 Dec; 5(12):4264-72. PubMed ID: 10632369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure-activity relationships, and inhibition of in vivo T cell activation.
    DiMauro EF; Newcomb J; Nunes JJ; Bemis JE; Boucher C; Chai L; Chaffee SC; Deak HL; Epstein LF; Faust T; Gallant P; Gore A; Gu Y; Henkle B; Hsieh F; Huang X; Kim JL; Lee JH; Martin MW; McGowan DC; Metz D; Mohn D; Morgenstern KA; Oliveira-dos-Santos A; Patel VF; Powers D; Rose PE; Schneider S; Tomlinson SA; Tudor YY; Turci SM; Welcher AA; Zhao H; Zhu L; Zhu X
    J Med Chem; 2008 Mar; 51(6):1681-94. PubMed ID: 18321037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of pyrimidine benzimidazoles as Lck inhibitors: part I.
    Zhang G; Ren P; Gray NS; Sim T; Liu Y; Wang X; Che J; Tian SS; Sandberg ML; Spalding TA; Romeo R; Iskandar M; Chow D; Martin Seidel H; Karanewsky DS; He Y
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5618-21. PubMed ID: 18793846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of pyrimidine benzimidazoles as Src-family selective Lck inhibitors. Part II.
    Zhang G; Ren P; Gray NS; Sim T; Wang X; Liu Y; Che J; Dong W; Tian SS; Sandberg ML; Spalding TA; Romeo R; Iskandar M; Wang Z; Seidel HM; Karanewsky DS; He Y
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6691-5. PubMed ID: 19854052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. E-novo: an automated workflow for efficient structure-based lead optimization.
    Pearce BC; Langley DR; Kang J; Huang H; Kulkarni A
    J Chem Inf Model; 2009 Jul; 49(7):1797-809. PubMed ID: 19552372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 56.